Clark Amelia M, DeDiego Marta L, Anderson Christopher S, Wang Jiong, Yang Hongmei, Nogales Aitor, Martinez-Sobrido Luis, Zand Martin S, Sangster Mark Y, Topham David J
David H. Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Division of Nephrology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, United States of America.
PLoS One. 2017 Nov 16;12(11):e0188267. doi: 10.1371/journal.pone.0188267. eCollection 2017.
Antigenic drift of the hemagglutinin (HA) and neuraminidase (NA) influenza virus proteins contributes to reduced vaccine efficacy. To analyze antigenic drift in human seasonal H1N1 viruses derived from the 2009 pandemic H1N1 virus (pH1N1-like viruses) accounts for the limited effectiveness (around 40%) of vaccination against pH1N1-like viruses during the 2015-2016 season, nasal washes/swabs collected from adult subjects in the Rochester, NY area, were used to sequence and isolate the circulating viruses. The HA and NA proteins from viruses circulating during the 2015-2016 season encoded eighteen and fourteen amino acid differences, respectively, when compared to A/California/04/2009, a strain circulating at the origin of the 2009 pandemic. The circulating strains belonged to subclade 6B.1, defined by HA amino acid substitutions S101N, S179N, and I233T. Hemagglutination-inhibiting (HAI) and HA-specific neutralizing serum antibody (Ab) titers from around 50% of pH1N1-like virus-infected subjects and immune ferrets were 2-4 fold lower for the 2015-2016 circulating strains compared to the vaccine strain. In addition, using a luminex-based mPlex HA assay, the binding of human sera from subjects infected with pH1N1-like viruses to the HA proteins from circulating and vaccine strains was not identical, strongly suggesting antigenic differences in the HA protein. Additionally, NA inhibition (NAI) Ab titers in human sera from pH1N1-like virus-infected subjects increased after the infection and there were measurable antigenic differences between the NA protein of circulating strains and the vaccine strain using both ferret and human antisera. Despite having been vaccinated, infected subjects exhibited low HAI Ab titers against the vaccine and circulating strains. This suggests that poor responses to the H1N1 component of the vaccine as well as antigenic differences in the HA and NA proteins of currently circulating pH1N1-like viruses could be contributing to risk of infection even after vaccination.
血凝素(HA)和神经氨酸酶(NA)流感病毒蛋白的抗原漂移导致疫苗效力降低。为分析源自2009年大流行H1N1病毒的人类季节性H1N1病毒(类pH1N1病毒)中的抗原漂移,其导致了2015 - 2016季节针对类pH1N1病毒疫苗接种效果有限(约40%),从纽约州罗切斯特地区的成年受试者收集的鼻洗液/拭子被用于对流行病毒进行测序和分离。与2009年大流行起源时流行的毒株A/California/04/2009相比,2015 - 2016季节流行病毒的HA和NA蛋白分别编码了18个和14个氨基酸差异。流行毒株属于6B.1亚分支,由HA氨基酸替换S101N、S179N和I233T定义。与疫苗毒株相比,约50%的类pH1N1病毒感染受试者和免疫雪貂的血凝抑制(HAI)和HA特异性中和血清抗体(Ab)滴度对于2015 - 2016流行毒株低2 - 4倍。此外,使用基于Luminex的mPlex HA检测,感染类pH1N1病毒受试者的人血清与流行毒株和疫苗毒株的HA蛋白的结合并不相同,强烈表明HA蛋白存在抗原差异。另外,类pH1N1病毒感染受试者的人血清中的NA抑制(NAI)Ab滴度在感染后增加,并且使用雪貂和人抗血清时,流行毒株和疫苗毒株的NA蛋白之间存在可测量的抗原差异。尽管已接种疫苗,但感染受试者对疫苗和流行毒株的HAI Ab滴度较低。这表明对疫苗H1N1成分反应不佳以及当前流行的类pH1N1病毒的HA和NA蛋白中的抗原差异可能导致即使接种疫苗后仍有感染风险。